Imugene Limited
ASX: IMU.AX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Leslie Chong
- Headquarters
- Sydney, Australia
- IPO year
- 1998
- Market cap
- A$43.7M
- Website
- https://www.imugene.com
Loading IMU…
Loading profile data…Frequently asked questions about IMU
What does Imugene Limited (IMU.AX) do?
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast ca...
Where does IMU.AX trade?
Imugene Limited (IMU.AX) trades on the Australian Securities Exchange.
What sector is IMU.AX in?
Imugene Limited (IMU.AX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Imugene Limited?
Leslie Chong is the chief executive officer of Imugene Limited (IMU.AX).
Where is Imugene Limited headquartered?
Imugene Limited is headquartered in Australia.
Does IMU.AX pay a dividend?
Imugene Limited (IMU.AX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IMU.AX go public?
Imugene Limited (IMU.AX) completed its initial public offering in 1998.